摘要
2019年底,由重症急性呼吸道综合征冠状病毒2(SARS-CoV-2)引起的新型冠状病毒病肺炎(COVID-19)在全球迅速蔓延,由于其潜伏期长、传播性强、突变率高,因此,COVID-19的防治已成为全球卫生领域的焦点问题。由于人体呼吸道黏膜表面血管紧张素转换酶2(angiotensin converting enzyme 2,ACE2)含量丰富,而SARS-CoV-2表面的刺突蛋白(S蛋白)具有介导受体识别和结合功能,其受体结构域可特异性结合ACE2的肽酶结构域。因此,ACE2是作为SARS-CoV-2感染的宿主的途径,在SARS-CoV-2感染机体过程中发挥至关重要的作用。与此同时,心肌组织ACE2含量较丰富,且COVID-19合并心肌损伤患者心肌组织ACE2呈现表达异常。而我国传统中医药六大处方防治COVID-19疗效显著,其中,共有中药单体成分槲皮素备受关注,防治机制可能与槲皮素抑制ACE2密切相关。迄今为止,少有SARS-CoV-2所致心肌损伤药物治疗的相关报道。因此,本文旨在通过文献汇总和生信预测探讨槲皮素是否通过抑制ACE2在心肌组织中的高表达从而改善COVID-19所致心肌损伤,从而降低COVID-19患者心源性死亡率及心血管并发症。
At the end of 2019,coronavirus disease 2019(COVID-19)caused by severe acute respiratory SARS coronavirus 2(SARS-CoV-2)spread rapidly around the world.Due to the rich content of angiotensin converting enzyme 2(ACE2)on the mucosal surface of human respiratory tract,and the spike protein(S protein)on the surface of SARS-COV-2 has the function of inducing receptor recognition and binding,Receptor binding domains can specifically bind peptidase domains of ACE2.Thus,ACE2 acts as a host pathway for SARS-COV-2 infection and plays a crucial role in sarS-COV-2 infection.At the same time,the myocardial tissue ACE2 content is abundant,therefore,the myocardial tissue of patients with COVID-19 combined with myocardial injury shows abnormal expression of ACE2.The six major prescriptions of traditional Chinese medicine have remarkable effects in the prevention and treatment of COVID-19.Among them,quercetin,a monomer component of traditional Chinese medicine,has attracted more attention,and the prevention and treatment mechanism may be closely related to the inhibition of ACE2 by quercetin.Up to date,there have been few reports on drug therapy for myocardial injury caused by SARS-CoV-2..Therefore,this paper aims to explore whether quercetin can improve myocardial injury caused by COVID-19 by inhibiting the high expression of ACE2 in myocardial tissue through literature summary and bioinformatics prediction,thereby reducing Vascular complications and cardiac mortality in patients with COVID-19.
作者
万敬强
郭振东
马永霞
谢萍
WAN Jing-qiang;GUO Zhen-dong;MA Yong-xia;XIE Ping(First Department of Cardiology,Gansu Provincial Hospital of TCM,Lanzhou 730000,Gansu,China;First Department of Cardiology,Gansu Provincial Hospital,Lanzhou 730000,Gansu,China)
出处
《心脏杂志》
CAS
2024年第2期215-219,共5页
Chinese Heart Journal
基金
国家自然科学基金地区科学基金项目(GZK-2018-42)
甘肃省国际科技合作项目(2019-0204-GJC-0006)
兰州市人才创新创业项目(2018-RC-72)
甘肃中医药大学研究生创新基金项目(LCCX2021007)。
作者简介
万敬强,住院医师,硕士,Email:2453750236@qq.com;通讯作者:谢萍,主任医师,主要从事心血管疾病的防治研究,Email:pingxie66@163.com。
